BioLight Israeli Life Sciences Investments Begins Trading on OTCQX®

     BioLight Israeli Life Sciences Investments Begins Trading on OTCQX®

PR Newswire

NEW YORK, Feb. 20, 2014

NEW YORK, Feb. 20, 2014 /PRNewswire/ --OTC Markets Group Inc. (OTCQX: OTCM),
operator of Open, Transparent and Connected financial marketplaces, today
announced that BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT;
OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical
innovations grouped into clusters around defined medical conditions, has
chosen to have its American Depositary Receipts (ADRs) trade on OTCQX®, ^ the
Best Marketplace with Qualified Companies.

OTC Markets Group logo.

BioLight ADRs, where each ADR represents 100 ordinary shares, begin trading
today under the symbol "BLGTY" on OTCQX International, a segment of the OTCQX
marketplace reserved for high-quality non-U.S. companies that are listed on a
qualified international exchange and provide their home country disclosure to
U.S. investors. U.S. investors can find current financial disclosures and
Real-Time Level 2 quotes for the company at

"We are pleased to welcome BioLight to the OTCQX marketplace," said R.
Cromwell Coulson, President and CEO of OTC Markets Group. "Led by its
Chairman Mr. Israel Makov, the former CEO and President of Teva
Pharmaceuticals, and world–renowned management team and base investors with
significant pharmaceutical and biomedical experience, BioLight is one of the
most exciting companies in Israel today. By initiating an ADR program and
trading on OTCQX, BioLight now has access to the world's largest pool of
investors to help accelerate growth while providing U.S. investors a quality
trading and information experience."

"We are delighted to have BioLight's ADRs begin trading on the OTCQX," said
Suzana Nahum Zilberberg, CEO of BioLight. "BioLight's business model offers
U.S. investors the opportunity for a single investment that provides access to
a robust portfolio of novel products, leveraging knowledge synergies and
economies of scale in therapeutic-specific clusters."

BNY Mellon serves as BioLight's Principal American Liaison ("PAL") on OTCQX,
and is responsible for providing professional guidance on OTCQX requirements.

About BioLight
BioLight invests in, manages and commercializes biomedical innovations grouped
into "clusters" around defined medical conditions. The two current clusters
are in ophthalmology via 100% ownership of XLVision Sciences and in cancer
diagnostics via a 29% controlling ownership of Micromedic (TASE: MCTC).
XLVision technologies include IOPtimate™, a laser-based noninvasive surgical
treatment for glaucoma; TeaRx, a point-of-care dry-eye syndrome diagnostic
test; and Eye-D™, a long-term controlled release drug-delivery implant
platform. Micromedic diagnostic tests are designed to detect colorectal,
cervical, breast, bladder, lung and other cancers. Base key investors,
holding about 55% of BioLight's shares, are Mr. Israel Makov, Chairman of Sun
Pharmaceuticals and Given Imaging and former CEO and President of Teva
Pharmaceuticals, with Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals,
India's largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of
Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel.

For more information please visit the Company's website at

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected
financial marketplaces for 10,000 U.S. and global securities. Through our OTC
Link® ATS, we directly link a diverse network of broker-dealers that provide
liquidity and execution services for a wide spectrum of securities. We
organize these securities into marketplaces to better inform investors of
opportunities and risks – OTCQX®, The Best Marketplace with Qualified
Companies; OTCQB®, The Venture Stage Marketplace with U.S. Reporting
Companies; and OTC Pink®, The Open Marketplace with Variable Reporting
Companies. Our data-driven platform enables investors to easily trade through
the broker of their choice at the best possible price and empowers a broad
range of companies to improve the quality and availability of information for
their investors. To learn more about how we create better informed and more
efficient financial marketplaces, visit

OTC Link® ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated

Subscribe to the OTC Markets RSS Feed


SOURCE OTC Markets Group Inc.

Contact: OTC Markets Group: Saskia Sidenfaden (, +1
(212) 896-4428; BioLight: Itai Bar-Natan, CFO (,
972-73-2753400; LHA: Kim Sutton Golodetz (, +1 (212)
838-3777; Or Bruce Voss (, +1 (310) 691-7100
Press spacebar to pause and continue. Press esc to stop.